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was increased by 10% per week until a
final dose of 69mJcm 2 was achieved.
That dose was maintained for the
remainder of the irradiation sessions.
Mice were photographed once weekly
from 14 to 30 weeks. All mice were
euthanized at the end of 30 weeks, and
the dorsal skin was collected as described
earlier. Mice with tumors exceeding the
size of 1ml were euthanized earlier as
necessary in accordance with IACUC
policies for tumor burden. Representa-
tive images of mice at week 30 are
shown in Figure 2a. In the absence of
SSL, neither cream vehicle nor aTd treat-
ments produced adverse skin conditions
(Figure 2a). Tumor onset occurred 4
weeks after the last irradiation session
(week 17 of study) in both groups, and
multiplicity was significantly slower in
weeks 20 to 23 in the aTd-treated group,
Po0.05 (Figure 2b). By week 22 (week 9,
post UV), 100% of the mice in the cream
vehicleþ SSL group were carrying UV-
induced tumors. This was significantly
higher compared with the aTd-treated
group, which showed 64% of mice carry-
ing tumors at the same time point
(Po0.0003). Tumor size and numbers
were recorded at 30 weeks, and the
percentage of larger tumors was obser-
ved to be higher in the cream vehicle only
group, P¼ 0.0006 (Figure 2c). Differ-
ences in the size of tumor may be
attributed to a faster growth rate in the
vehicle-treated group, leading to advan-
ced severity of the tumor (de Gruil and
van der Leun, 1991). After 30 weeks, of
the mice that exhibited tumors in the aTd
group, there were 18% fewer tumors as
compared with the vehicle-treated group,
P¼ 0.18, and 27% fewer tumors overall
in the aTd-treated group, P¼ 0.08.
In this study, we have demonstrated
that aTds act as structural mimetics of
DNA and its topical treatment resulted
in significant DNA photoprotection in
both mouse and human skin exposed to
acute UVB and reduced UV-induced
skin tumor development in chronic
UV-irradiated mice. We continue to
work on delineating the mechanistic
aspects of the observed DNA photo-
protection, including a possible role in
DNA repair. Concomitantly, we are
examining aTd’s role in skin anti-aging
based on chronic UV studies.
All studies involving mice were
reviewed and approved by the Univer-
sity of Minnesota Institutional Animal
Care and Use Committee (IACUC).
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TO THE EDITOR
Although only about 15% of non-Hodg-
kin lymphomas are T-cell lymphomas,
the treatment of this subset of neoplasms
remains a significant challenge in the
field of hematological cancers owing to
unclear mechanisms regulating malig-
nant T-cell growth. Cutaneous T-cell
lymphoma (CTCL) identifies a group of
extranodal T-cell lymphomas character-
ized by the infiltration of malignant
CD4þ T cells in the skin (Wong et al.,
2011). Se´zary syndrome (SS) is an
aggressive subtype of CTCL defined byAccepted article preview online 24 July 2013; published online 22 August 2013
Abbreviations: CTCL, cutaneous T-cell lymphoma; PBMCs, peripheral blood mononuclear cells;
SAMHD1, sterile alpha motif and hemidesmosome domain containing protein 1; SS, Se´zary syndrome
S de Silva et al.
SAMHD1 Downregulation in Se´zary Syndrome
562 Journal of Investigative Dermatology (2014), Volume 134
diffuse pruritic rash, lymphadenopathy,
and malignant T cells in the peripheral
blood. The mechanisms underlying the
proliferation of neoplastic CD4þ T cells
in SS are not fully understood, but
abnormal epigenetic regulation of gene
expression including silencing of tumor
suppressor genes likely has an important
role (van Doorn et al., 2005). Epigenetic
mechanisms act as critical contributors
in cancer initiation and progression
through modulation of gene expres-
sion, and transcriptional repression of
tumor suppressor genes via epigenetic
mechanisms occurs in many cancers
(Baylin and Jones, 2011).
Sterile alpha motif and hemidesmo-
some domain containing protein 1
(SAMHD1) is the first identified mam-
malian triphosphohydrolase that hydro-
lyzes deoxynucleoside triphosphates,
implicating a role in nucleic-acid meta-
bolism (Goldstone et al., 2011).
SAMHD1 acts as an HIV-1 restriction
factor in myeloid cells and in quiescent
CD4þ T cells by diminishing the intra-
cellular deoxynucleoside triphosphate
pool to a level that is insufficient for
viral replication (Baldauf et al., 2012;
Lahouassa et al., 2012). Non-dividing
CD4þ T cells, monocytes, macro-
phages, and dendritic cells from
healthy individuals express high levels
of SAMHD1 protein and have signifi-
cantly lower levels of intracellular
deoxynucleoside triphosphates com-
pared to activated CD4þ T cells, while
several leukemia/lymphoma CD4þ
T-cell lines lack SAMHD1 protein expres-
sion and have increased deoxynucleo-
side triphosphate levels necessary for
cell division (Hrecka et al., 2011;
Laguette et al., 2011; Baldauf et al.,
2012). We found that promoter methy-
lation represses SAMHD1 expression in
human leukemia/lymphoma CD4þ T-cell
lines, while the SAMHD1 promoter
is unmethylated in primary CD4þ
T-lymphocytes from healthy donors that
express high levels of SAMHD1 protein
(de Silva et al., 2013). The role of
SAMHD1 in cancer remains unknown.
To explore the potential role of
SAMHD1 in CTCL, we measured
SAMHD1 mRNA levels in peripheral
blood mononuclear cells (PBMCs) taken
from 14 healthy donors and 9 CTCL
patients using a real-time quantitative-
PCR assay (de Silva et al., 2013). The
patients comprised eight with SS and
one with advanced-stage mycosis
fungoides (Table 1), which are two
related subtypes of CTCL originating
from CD4þ skin-homing T cells
(Wong et al., 2011). Interestingly, quan-
titative-PCR results revealed that PBMCs
from the 8 SS patients and an advanced-
stage mycosis fungoides patient
expressed on average threefold lower
SAMHD1 mRNA levels (P¼0.0013,
two-sample t-test) compared with those
from 14 healthy donors (Figure 1a and
Table 1). These results indicate that
SAMHD1 expression is significantly
downregulated in PBMCs from SS
patients relative to healthy individuals.
Next, we examined whether the
downregulation of SAMHD1 mRNA
levels would translate to reduced
SAMHD1 protein levels in PBMCs of
CTCL patients. To this end, we mea-
sured expression levels of surface CD4
and intracellular SAMHD1 proteins in
PBMCs from three CTCL patients with
high circulating neoplastic T cells
(patient 3, 4, and 5 in Figure 1b and
Table 1) and four healthy donors using
immunostaining and flow cytometry
(Figure 1b) (Descours et al., 2012). The
limited sample size was because of
Table 1. Clinical information of CTCL patients and relative levels of SAMHD1 mRNA and promoter methylation in
PBMCs from the patients
Patient
no.
CTCL
subtype1
Disease
stage
CD4þ
cells (%)2
Absolute
CD4 count
CD4:CD8
ratio
Se´zary
cell count (%)
Relative SAMHD1 mRNA
levels3
Relative SAMHD1
promoter
methylation
levels4
#1 SS IVA 98 N/A N/A 29 0.079 30.74
#2 SS IVA 93 N/A N/A 45 0.995 39.31
#3 SS IVA2 80 N/A N/A 31 0.217 0.000
#4 SS IVA 65 N/A N/A N/A 0.387 19.43
#5 SS IVA2 78 N/A N/A 61 0.469 135.79
#6 MF IIB 30 163 1.8 N/A 0.048 92.27
#7 SS IVA 85 1785 28 N/A 0.483 19.34
#8 SS IVA2 88 3346 82 N/A 0.229 43.29
#9 SS IVA 82 1466 13 N/A 0.441 81.32
Abbreviations: CTCL, cutaneous T-cell lymphoma; MF, mycosis fungoides; N/A, not available; SAMHD1, sterile alpha motif and hemidesmosome domain
containing protein 1; SS, Se´zary syndrome.
1No patient in this group was treated with methotrexate. These patients have been on bexarotene and IFN at some time during their treatments.
2CD4þ cells (%) indicate percentage of CD4-positive cells in patient PBMCs by flow cytometry analysis.
3Relative levels of SAMHD1 mRNA in PBMCs from 9 CTCL patients (mean±SD is 0.372±0.285) compared with the average level of 14 healthy donors
(1.113±0.553).
4Relative levels of SAMHD1 promoter methylation in PBMCs from 9 CTCL patients (mean±SD is 51.27±43.32) compared with the average level of 8 healthy
donors (1.000±1.703).
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thePBMCs being available only from
three CTCL patients. The percentage of
total SAMHD1-positive cells in PBMCs
from CTCL patients (37±9%) was sig-
nificantly lower (P¼0.0024) than that
from healthy donors (71±6%) (Figure 1c).
Furthermore, the percentage of SAMHD1-
expressing cells in CD4-negative PBMCs
from CTCL patients (3±2%) was signifi-
cantly lower than that from healthy
donors (19±8%) (P¼0.023). Analysis
of SAMHD1 and CD4 double-positive
cells in PBMCs from CTCL patients
(34±9%) and healthy donors (52±
8%) showed a statistical difference
(P¼ 0.042), suggesting significant down-
regulation of SAMHD1 protein expres-
sion in the neoplastic CD4þ cell subset
from CTCL patients. Given that PBMCs
from CTCL patients comprise mainly
CD4þ cells, we also compared the
percentage of SAMHD1-expressing cells
in the CD4þ gated population between
healthy donor samples (81±3%) and
CTCL patient samples (46±6%) and
found a significant reduction (P¼0.0024)
in SAMHD1-expressing cells (Supple-
mentary Figure S1 online).
We hypothesized that the SAMHD1
promoter in PBMCs from the CTCL
patients is methylated and thereby inhi-
bits SAMHD1 expression. To compare
the methylation status of the SAMHD1
promoter in PBMCs from the CTCL
patients selected with that from healthy
donors, genomic DNA of PBMCs was
treated with the methylation-sensitive
HpaII endonuclease, or left untreated,
and then subjected to PCR amplification
using SAMHD1 promoter-specific
primers as described (de Silva et al.,
2013). The SAMHD1 promoter con-
tains five HpaII sites, and methylation
of these sites prevents digestion by
HpaII. The intact undigested sequence
can serve as a template for PCR
amplification to yield a 1.2-kb product.
As an input control of genomic DNA,
a 0.25-kb region within the glyceral-
dehyde-3-phosphate dehydrogenase
gene lacking HpaII sites was PCR
amplified (Supplementary Figure S2
online). The SAMHD1 promoter in
PBMCs from eight of nine CTCL patients
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Figure 1. Comparison of SAMHD1 expression levels and the SAMHD1 promoter methylation in PBMCs from CTCL patients and healthy donors. (a) SAMHD1
mRNA levels in PBMCs from 14 healthy donors and 9 CTCL patients (refer to Table 1) were measured by quantitative-PCR and normalized to glyceraldehyde-3-
phosphate dehydrogenase levels. The average levels of SAMHD1 mRNA levels are shown. The error bars represent standard error of the mean. (b) Intracellular
SAMHD1 and surface CD4 proteins in PBMCs from CTCL patients and healthy donors were detected by immunostaining and flow cytometry. Donor and patient
numbers are indicated above the plots. The percentages of cells positive for CD4 only (upper left quadrant), SAMHD1 only (lower right quadrant), or double
positive for CD4 and SAMHD1 (upper right quadrant) are indicated. (c) Flow cytometry-based quantification of SAMHD1-expressing (þ ) cells in PBMCs from
healthy donors and CTCL patients. (d) Quantification of relative levels of SAMHD1 promoter methylation in PBMCs from nine CTCL patients and eight healthy
donors. ImageJ program was used to quantify the intensity of the SAMHD1 promoter-specific PCR bands in Supplementary Figure S2, and the relative level of
methylation was calculated by setting the intensity of the HpaII-untreated sample as 100 and calculating the percentage intensity of the PCR band in the HpaII-
treated samples relative to its matching untreated control. The error bars represent standard error of the mean.
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tested was methylated (Supplementary
Figure S2a online, 1.2-kb bands).
Strikingly, PBMCs from eight healthy
donors showed that the SAMHD1 pro-
moter was unmethylated (Supple-
mentary Figure S2b online). The purity
of the genomic DNA for complete
enzyme digestion as well as the intact
nature of the HpaII sites in the SAMHD1
promoter sequence in healthy donor
and CTCL patient genomic DNA
was confirmed by restriction digestion
with MspI (an isoschizomer of HpaII),
which cleaves the HpaII site irrespective
of its methylation status (Supplementary
Figure S3 online).
Densitometry analysis of the PCR
products in Supplementary Figure S2
online was used to quantify the relative
level of methylation of the SAMHD1
promoter in PBMCs from CTCL patients
and healthy donors. Our analysis
revealed 51-fold higher average levels
of methylation of the SAMHD1 promo-
ter in PBMCs from nine CTCL patients
(P¼ 0.0052) relative to eight healthy
donors (Figure 1d and Table 1). These
results suggest a positive correlation
between downregulation of SAMHD1
expression and methylation of the
SAMHD1 promoter in PBMCs from
CTCL patients. However, we observed
a lack of correlation between reduced
SAMHD1 expression and promoter
methylation in patient 3, which suggests
that, besides promoter methylation,
other transcriptional and epigenetic reg-
ulatory mechanisms, such as microRNA
and histone modifications, may also
contribute to the regulation of SAMHD1
expression in CTCL patients.
SAMHD1 somatic mutations have
been identified in patients with lung
adenocarcinoma, medulloblastoma,
glioblastoma, breast, pancreatic, and
colorectal cancers, albeit at a very low
frequency (Sjoblom et al., 2006; Jones
et al., 2008; Parsons et al., 2008, 2011;
Imielinski et al., 2012). Transcriptional
repression of tumor suppressor genes
through DNA methylation and
histone modifications is a common
mechanism of gene silencing in
numerous types of cancer. Inhibition of
epigenetic suppression in vitro using
specific inhibitors to block DNA methy-
ltransferase and/or histone deacetylase
can reactivate the expression of tumor
suppressor genes silenced in cancer.
Downregulation of dNTP catabolic
enzymes such as SAMHD1 may lead
to imbalances in the intracellular dNTP
pool, which can induce mutations and
genomic instability as key features
of CTCL.
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